Clinical Trials
6 trialsNCT06686394 2026-05-22
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05319873 2026-05-11
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04285671 2026-03-10
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04108858 2025-10-01
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00238420 2022-07-19
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed